



# Acil Laboratuvarlarda Kan Sayım ve Preanalitik Hata Kaynakları

Fatma Uçar


TC. SB.SBÜ.

Dışkapı Yıldırım Beyazıt  
Eğitim ve Araştırma Hastanesi  
Preanalitik Evre Sempozyumu

17 Nisan 2019



Türk Biyokimya Derneği  
Turkish Biochemical Society



# İçerik

- ✓ Laboratuvar Hatası
- ✓ Preanalitik Evre
- ✓ Preanalitik faktörler
- ✓ Literatür örnekleri
- ✓ Sonuç ve Öneriler

# Laboratuvar Hatası


‘Test isteminden sonuçların raporlanmasına ve test sonuçlarının uygun şekilde yorumlanıp etki etmesine kadar laboratuvar döngüsünün herhangi bir bölümünde gerçekleşen, planlanan bir eylemin amaçlanan şekilde yerine getirilmemesi veya amaca ulaşabilmek için yanlış plan yapılması ve kullanılması’

*ISO/PDTS 22367 Medical laboratories-reduction of error through risk management and continual improvement-complementary elements*



# Brain to Brain Turnaround Time Loop

- 1970 Gambino
- 1981'de Lundberg
- 9 Basamak
  1. Ordering
  2. Collection
  3. Identification
  4. Transportation
  5. Preparation
  6. Analysis
  7. Reporting
  8. Interpretation
  9. Action



# Hata Oranları

- Pre-pre analitik fazda **% 46-68.2**
- Pre-analitik faz **% 3.0-5.3**
- Analitik faz **% 7-13**
- Post-analitik faz **% 12.5-20**
- Post-post-analitik faz **% 25-45.5**
- *Giorgio Da Rin. Pre-analytical Workstations As A Tool For Reducing Laboratory Errors. J Med Biochem 29: 315-324, 2010*




Figure 1 Types and rates of error in the three stages of the laboratory testing process (modified from reference 3).

*Mario Plebani. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 2006;44(6):750-759*

# Preanalitik Faktörler

## Hastaya Ait Faktörler

- Irk
- Cinsiyet
- Yaş
- Gebelik
- Diyet
- Egzersiz
- Obezite
- Yaşam Biçimi
- Çevresel Faktörler
- Tedavi durumu

## Örnek Alımı

- Hastanın kimliklendirilmesi
- Postür
- Diurnal Varyasyon
- Örnek Alma Zamanı
- Açlık durumu
- Turnike uygulanması
- IV tedavi
- Örnekleme yeri
- Antikoagülan tipi
- Kan almada tüp sırası
- Örnek Hacmi
- Kan alma iğne çapı


## Örnek İşlenmesi

- Etiketleme
- Transport
- Sıcaklık
- Işık
- Saklama
- Hemoliz
- Lipemi
- Santrifüj
- Isı

**IRK**



**CINSİYET**



**YAŞ**



**PREGNANCY**



**GEBELİK**



**RAKIM**



**SİGARA**

# Hasta Kimliklendirilmesi

- **CLSI 41- A6 Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard—Sixth Edition**
- En az 2 bağımsız tanımlayıcı olmalıdır.
- Aktif olmalı ve açık uçlu bir soru sorulmalı  
*Adınız nedir ?*  
*Doğum tarihiniz nedir?*
- **EFLM WG-PRE** ise en az 2 tercihen 3 bağımsız tanımlayıcı soru sorulmalı, biri mutlaka ad-soyad olmalı
- Tanımlama hataları **% 0.1-5\***

\*2006 Q-Probes study of 120 institutions Valenstein et al, Arch Pathol Lab Med 130:1106-13, 2006






# Postür


- **CLSI GP 41-A6 klavuzu:** Kan örneklerinin uygun bir sandalyeye rahatça oturarak veya uzanırken alınmasını önermektedir.
- **WHO klavuzu:** Mümkünse hastayı supin pozisyonunda rahat olmasını sağlayın gibi bir ifade yer alır.
- Yatar pozisyondan oturma pozisyonuna geçişte plazma hacminin azalması nedeniyle

Hb  
Htc  
RBC  
WBC  
PLT



- Birkaç günlük yatak istirahatinde plazma ve ekstrasellüler mayi hacmi düşer. Bu sebeple **Htc %10** artar.

- *Oliveria G.L. Et al. Patient posture for blood collection by venipuncture: recall for standardization after 28 years. rev bras hematol hemoter. 2017;39(2):127-132*



# Diurnal Varyasyon



- Hb, Htc ve RBC öğlen 12 civarı pik değer gösterirken, gece 00.00 civarı ise en düşük değeri göstermektedir.
- WBC, nötrofil, lenfosit ve eosinofil ise gece en yüksek değerde iken öğle vakti en düşük değeri göstermektedir.
- *Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2011;71:532-41.*

# Stress

- Özellikle çocuklarda olmak üzere kan alma korkusu olan hastalarda ciddi ajitasyon sonrası **lökositoz** ve **nötrofili** görülebilir.



# Fiziksel Egzersiz




Fig. 1. Leukocyte concentration in response to different exercise intensities in physically active men \*versus the baseline, †versus the control session, and §versus LIE. HIE = high-intensity exercise; LIE = low-intensity exercise.

*P.R.D.S. Neves et al. Acute effects of high- and low-intensity exercise bouts on leukocyte counts. Journal of Exercise Science & Fitness 13 (2015) 24-28.*

- *Plazma volüm değişiklikleri*
- *Artan bazal metabolizma hızı*
- *Reaktif oksijen türleriyle ilişkili olarak artan hücresel hasar*
- nedeni ile ilgili olarak tam kan sayım sonuçları egzersizden etkilenebilir.


# Açlık Durumu




Hafif bir öğün;

- Nötrofillerde artış,
- Lenfositlerde ve eozinofillerde yemekten sonra 4 saate kadar önemli azalma
- RBC, Hb ve Htc'de azalma

- *Lippi G. Et al. Influence of a light meal on routine haematological tests. Blood Transfus. 2010 Apr;8(2):94-9. doi: 10.2450/2009.0142-09*



**Figure 1** - Percentage post-prandial variation of red blood cell count (RBC), haemoglobin concentration (HGB), haematocrit (HCT), mean corpuscular haemoglobin (MHC), mean corpuscular volume (MCV) and RBC distribution width (RDW) after a light meal.



**Figure 2** - Percentage post-prandial variations of white blood cell (WBC) count, neutrophils (NEU), lymphocytes (LYMP), monocytes (MONO), eosinophils (EOS), basophils (BASO) and large unstained cells (LUC) after a light meal.

*Lippi G. Et al. Influence of a light meal on routine haematological tests. Blood Transfus. 2010 Apr;8(2):94-9. doi: 10.2450/2009.0142-09*




Figure 1. Variability on laboratory tests due to food intake 4 hours before blood collection by venipuncture. Variability is expressed as difference (bias, %) from 4 h fasting (during day) compared to 12 h fasting (overnight). This Figure was constructed from results previously published by Lima-Oliveira et al. and Lippi et al. [13,14]. Black bars, higher than desirable specification derived from biologic variation; grey bar, lower than desirable specification derived from biologic variation. K, potassium; Phos, phosphate; Alb, albumin; Ca, calcium; Mg, magnesium; Hb, haemoglobin; RBC, red blood cells; Lympho, lymphocytes; TB, total bilirubin; Eos, eosinophils.

***Oliveira GL. et al. Pre-analytical phase management: a review of the procedures from patient preparation to laboratory analysis. Scandinavian Journal Of Clinical And Laboratory Investigation, 2017 VOL. 77, NO. 3, 153–163.***

# Turnike

- 7.5-10.0 cm. (3-4 parmak)
- 60 sn den fazla tutulmamalıdır.
- Venöz staz (60 saniyeden uzun) kan damarlarından su, iyon ve düşük moleküler ağırlıklı maddelerin çıkışını teşvik eder, böylelikle damar delme bölgesinde biyobelirteçlerin konsantrasyonunu arttırır.




Figure 3. Venous stasis due to tourniquet application. (A1). Schematic upper limb without tourniquet application; (A2) Schematic blood vessels at physiological condition. (B1) Schematic upper limb after tourniquet application; (B2) Schematic blood vessels over tourniquet application; (B3) Schematic blood vessels at venous stasis condition due to tourniquet application by more than 1 minute.

*Oliveira GL. et al. Pre-analytical phase management: a review of the procedures from patient preparation to laboratory analysis. Scandinavian Journal Of Clinical And Laboratory Investigation, 2017 VOL. 77, NO. 3, 153–163.*



**Table 3.** Impact of physiology disturbance on vein caused by two different source of variability (vein stasis by tourniquet application and cold with vibration by Buzzy®) on routine haematological testing [48,55].

Parameters	Source of variability				
	Tourniquet application by				Cold and vibration by Buzzy®
	60 s	90 s	120 s	180 s	
PLT	3.4 ( $p < .05$ )	3.6 ( $p < .01$ )	4.9 ( $p < .01$ )	4.1 ( $p < .01$ )	-0.7 (NS)
WBC	2.5 ( $p < .01$ )	4.8 ( $p < .01$ )	4.9 ( $p < .01$ )	3.1 ( $p < .01$ )	-3.5 ( $p < .01$ )
NEU	3.3 ( $p < .01$ )	4.2 ( $p < .01$ )	6.6 ( $p < .01$ )	3.9 ( $p < .01$ )	-2.9 ( $p < .05$ )
MONO	4.3 ( $p < .01$ )	3.9 ( $p < .05$ )	3.6 (NS)	3.7 (NS)	-3.6 (NS)
EOS	4.2 ( $p < .05$ )	24.1 ( $p < .01$ )	7.5 (NS)	3.8 ( $p < .05$ )	0.0 (NS)
LYMP	0.8 (NS)	2.6 ( $p < .01$ )	5.6 ( $p < .01$ )	2.8 ( $p < .05$ )	-3.9 ( $p < .05$ )
RBC	1.5 ( $p < .01$ )	2.8 ( $p < .01$ )	2.8 ( $p < .01$ )	4.7 ( $p < .01$ )	2.0 ( $p < .001$ )
Hb	1.3 ( $p < .01$ )	2.6 ( $p < .01$ )	2.7 ( $p < .01$ )	4.1 ( $p < .01$ )	2.5 ( $p < .001$ )
Hct	1.5 ( $p < .01$ )	2.9 ( $p < .01$ )	2.9 ( $p < .01$ )	4.3 ( $p < .01$ )	2.2 ( $p < .001$ )

Results are expressed as percentage of variation (%) from the source of variability compared to the no-stasis by transilluminator. NS: not statistically significant ( $p > .05$ ). All data presented in this table were previously published by *International Journal of Laboratory Hematology* (ISSN 1751-553X) and *Blood Transfusion* (ISSN 1723-2007).

***Oliveira GL. et al. Pre-analytical phase management: a review of the procedures from patient reparation to laboratory analysis. Scandinavian Journal Of Clinical And Laboratory Investigation, 2017 VOL. 77, NO. 3, 153–163.***

# Transluminatör

**Transillumination: a new tool to eliminate the impact of venous stasis during the procedure for the collection of diagnostic blood specimens for routine haematological testing**

G. LIMA-OLIVEIRA<sup>\*,†,‡,§</sup>, G. LIPPI<sup>¶</sup>, G. L. SALVAGNO<sup>§</sup>, M. MONTAGNANA<sup>§</sup>, M. SCARTEZINI<sup>\*</sup>, G. C. GUIDI<sup>§</sup>, G. PICHETH<sup>\*</sup>



## SUMMARY

**Introduction:** The collection of diagnostic blood specimens for routine haematological testing (RHT) is traditionally performed with tourniquet. However, the transillumination devices based on cold near-infrared LEDs have been formerly proposed as a valuable tool for identifying reliable venous accesses, especially in patients with difficult or small veins, such as children. This study was aimed to evaluate whether a transillumination device can advantageously replace the use of the tourniquet during the procedure for collection of blood specimens for RHT and thereby eliminating the discomfort and risk of spurious results caused by excessive or prolonged venous stasis.

**Methods:** Two hundred and fifty volunteers were divided into five groups (G1, G2, G3, G4 and G5) to compare the results of RHT between blood sample collected with transilluminator device (left arm) and with tourniquet application (right arm) for 30 s(G1), 60 s(G2), 90 s(G3), 120 s(G4) and 180 s(G5).

**Results:** No significant increases were observed in any of the haematological parameters tested in G1 when compared with blood collected by the transilluminator device. From G2 to G5, significant increases were observed for the platelet count, red blood cell count, haemoglobin, haematocrit, white blood cell count, neutrophils, monocytes and eosinophils. From G3–G5, further increases were observed for lymphocytes. Clinically significant variations were, however, observed for basophils in G2; red blood cell count, haemoglobin, haematocrit and basophils in G3 and eosinophils in G3 only.


**Conclusion:** As such, considering that inappropriate use of the tourniquet is commonplace, we conclude that transillumination devices can represent a suitable tool to eliminate the venous stasis and to improve the quality of phlebotomy procedures.

# Buzzy®

- Kan alma esnasında damarın delinmesi sırasında oluşan ağrıyı azaltmak için üretilmiş soğutmalı buz paketi ve titreşim sağlayan bir alet

- Potansiyel preanalitik varyasyon kaynağı

- WBC
  - Nötrofil
  - Lenfosit
- 


- RBC
  - Hb
  - Htc
- 



# Yumruk Açıp Kapama


**TABLE 1** Impact of fist clenching and maintenance during blood collection by venipuncture for routine hematology testing

Parameter	Unit	Fist clenching	No fist clenching	P	Mean % difference	Desirable imprecision (%)	CVa %
RBC	10 <sup>12</sup> /L	4.53 [4.22-4.84]	4.46 [4.15-4.90]	.422	1.5	1.6	1.2
HGB	g/L	135 [126-139]	134 [124-137]	.151	0.7	1.4	1.6
HCT	%	40.3 [38.8-41.7]	39.4 [37.6-41.6]	.132	2.2	1.4	1
MCV	fL	89.8 [85.8-92.0]	88.7 [85.5-91.7]	<.001	1.2	0.7	0.5
RDW	%	13.9 [13.4-14.4]	13.9 [13.3-14.4]	.041	0	1.8	1
WBC	10 <sup>9</sup> /L	5.36 [4.69-7.34]	5.52 [4.84-7.48]	.352	-3	5.7	1.9
NEU	10 <sup>9</sup> /L	2.55 [2.30-4.33]	2.78 [2.58-4.29]	.535	-9	8.6	1.7
LYMPHO	10 <sup>9</sup> /L	2.01 [1.83-2.51]	2.08 [1.74-2.72]	.389	-3.5	5.1	2.3
MONO	10 <sup>9</sup> /L	0.30 [0.25-0.44]	0.31 [0.27-0.42]	.183	-3.3	8.9	6.5
EOS	10 <sup>9</sup> /L	0.15 [0.09-0.22]	0.17 [0.08-0.24]	.363	-13.3	10.5	7.8
BASO	10 <sup>9</sup> /L	0.03 [0.01-0.04]	0.03 [0.02-0.04]	.192	0	14	13
LUC	10 <sup>9</sup> /L	0.10 [0.07-0.12]	0.10 [0.08-0.14]	.977	0	NA	10.5
PLT	10 <sup>9</sup> /L	226 [166-278]	234 [169-286]	.979	-3.5	4.6	2.4
MPV	fL	9.30 [8.92-9.50]	9.25 [8.90-9.80]	.343	0.5	2.2	1.3
RETIC	10 <sup>9</sup> /L	60.6 [46.4-78.3]	55.6 [48.4-71.4]	.066	8.2	5.5	3.2



**Gabriel Lima-Oliveira, Gian Cesare Guidi, Gian Luca Salvagno, Giuseppe Lippi. The impact of fist clenching and its maintenance during venipuncture on routine hematology testing. J Clin Lab Anal 2016; 1–4**

# IV Tedavi



**Figure 1:** Pattern of cell blood counts including hemoglobin (A), hematocrit (B), white blood cells (C), and platelet (D) changes following infusion of one liter normal saline at the time of study. \*\* Significant difference from pre-treatment time at level  $p < 0.001$ . \* Significant difference from baseline at level  $p < 0.01$ . # Significant difference from baseline at level  $p < 0.05$ . [↑](#)




Figure 7. Venepuncture performed near a glucose infusion. Blood sample from that patient was diluted (Hb low) and excess of glucose led to a swelling of RBC: MCV was spuriously high and in turn MCHC spuriously low. Sample drawn correctly by the next morning showed normal values (no transfusion had been performed). RBC histogram on diluted sample (left) and on new sample (right; Beckman Coulter STKS II).

*M. ZANDECKI, F. GENEVIEVE, J. GERARD, A. GODON. Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. doi:10.1111/j.1365-2257.2006.00870.x*

# Kan Alma Bölgesi




Figure 2. Venipuncture sites at upper limb.

- Cilt yüzeyine yakın ve geniş venlerin bulunduğu dirseğin ön yüzü ve kolun iç kısmı venöz kan almada tercih edilen bölgedir (antekübital fossa).
  - Pediatrik hastalarda kapiller kan tercih edilebilir.
  - Hb
  - Htc
  - RBC
  - MCV
- Kapiller kanda daha yüksek
- Kapiller kanda daha düşüktür.

# Tüp Sırası

Tablo 3. İstemi yapılan testlerin özelliklerine göre alınacak numune tüpleri için uyulması gereken kan alma sırası ve altüst çevirme

Kapak rengi	Tüp/Katkı maddesi	Altüst çevirme sayısı
Değişken (1)	Kan kültürü/Besiyeri	Besiyeri ile kan karışımını sağlamak için hafifçe altüst edilir
(2)	Katkısız cam veya plastik serum tüpü	Gerek yok
(3)	Koagülasyon tüpü/Sitratlı	3-4 kez
(4)	ESR tüpü/Sitratlı	3-4 kez
(5)	Serum tüpü/ Jelsiz	5 kez
(5)	Serum tüpü/Jelli	5 kez
(5)		5 kez
(5)	Serum tüpü/Trombin pıhtı aktivatörlü tüp	5 kez
(6)	Plazma tüpü/Jelli veya jelsiz heparinli tüp	8-10 kez
(7)	Plazma tüpü/Jelli veya jelsiz EDTA'lı tüp	8-10 kez
(8)	Plazma tüpü/ Florür/potasyum okzalate;Florür/EDTA Florür/heparin	8-10 kez

EDTA; etilendiamin tetraasetik asit, ESR; eritrosit sedimantasyon hızı

DE GRUYTER

Clin Chem Lab Med 2017; 55(2): 27–31



## Opinion Paper

Michael Cornes\*, Edmée van Dongen-Lases, Kjell Grankvist, Mercedes Ibarz, Gunn Kristensen, Giuseppe Lippi, Mads Nybo and Ana-Maria Simundic, on behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)


## Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)

Table 1: Recommended order of blood draw.

1. Blood culture tube
2. Coagulation tube
3. Serum tube with or without clot activators, with or without gel
4. Heparin tubes with or without gel
5. EDTA tubes
6. Glycolytic inhibitor tubes
7. Other tubes (e.g. trace elements)



# EDTA Kontaminasyonu




*Oliveira GL. et al. Pre-analytical phase management: a review of the procedures from patient preparation to laboratory analysis. Scandinavian Journal Of Clinical And Laboratory Investigation, 2017 VOL. 77, NO. 3, 153–163.*

# EDTA Kontaminasyonu

- Hipernatremi (Na sitrat veya NaEDTA kontaminasyonu)
  - Hiperkalemi (KEDTA kontaminasyonu)
  - Hipokalsemi (EDTA kontaminasyonu)
  - Çinko düşüklüğü (EDTA kontaminasyonu)
  - Demir düzeyinde düşüklük (EDTA kontaminasyonu)
  - ALP düzeyinde düşüklük (EDTA kontaminasyonu)
  - Antikoagülanların transferi nedeniyle zayıf pıhtılaşma
  - Bir numunenin başka bir numuneye dökülmesi nedeniyle dilüsyon etkileri
- 
- *Michael Cornes, Edmée van Dongen-Lases, Kjell Grankvist, Mercedes Ibarz, Gunn Kristensen, Giuseppe Lippi, Mads Nybo and Ana-Maria Simundic, on behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE) Clin Chem Lab Med 2017; 55(1): 27–31*

# EDTA

- EDTA(Etilendiamintetraasetik asit)tuzları;
  - *Dipotasyum EDTA*
  - *Tripotasyum EDTA*
  - *Disodyum EDTA*
- Hematolojik testler için yaygın olarak kullanılan bir antikoagülandır.
- Kandaki kalsiyumu bağlayarak koagülasyon kaskadını inhibe eder.




# EDTA

- **K<sub>2</sub>EDTA** :Plastik tüplerin iç yüzeyine spreylenerek kurutulmuş bir solüsyondur.
- **K<sub>3</sub>EDTA** :Sıvı bir solüsyon halinde tüplerin içinde bulunur.




# EDTA Tuzları



- EDTA nın pH değeri tuzuna bađlı olarak deđiřir.
- EDTA pH=2.5±1.0 (serbest asit solüsyonu olarak)
- K<sub>3</sub>EDTA pH=7.5±1.0
- Na<sub>2</sub>EDTA pH=5.0±1.0
- K<sub>2</sub>EDTA pH=4.8±1.0

# EDTA

- Bu pH deęerindeki farklılıklar eritrosit boyutlarını etkiler.
- EDTA'nın tüm tuzları hücrelerden su kaybı ve hücre küçülmesine yol açan hiperosmolar moleküller olmalarına rağmen bu küçülme etkisi yalnızca  $K_3EDTA$  ile dikkati çekmektedir.
- $K_2EDTA$  ve  $NA_2EDTA$  ile hücre büzülmesi olmasına rağmen, düşük pH in hücre şişmesine neden olması ile oluşan osmotik dengelenme sonucu hücre boyutu deęişmez.



# K<sub>3</sub>EDTA

- K<sub>3</sub>EDTA **MCV** deęerlerinde K<sub>2</sub>EDTA ile karřılařtırıldıęında **%0.1-1.3** lük **azalmaya** neden olur.
- K<sub>3</sub>EDTA sıvı olması nedeni ile orneęin dilüsyonuna neden olur.
- Doğrudan ölçülen bütün deęerlerin (**Hb,Htc,RBC,WBC,PLT**) K<sub>2</sub>EDTA ile ölçülen deęerlere göre **%1-2** daha düşük çıkmasına neden olur.





# GP42-A6

## Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard—Sixth Edition

### 16.1.1 Additives

Hematology specimens can be collected directly into tubes containing EDTA (currently, dipotassium EDTA is the recommended type [see CLSI/NCCLS document H01]<sup>41</sup>); such specimens are stable for 2 to 12 hours and provide accurate hematologic results.<sup>42</sup> Since heparin distorts cell morphology and interferes with cell staining, specimens for hematology tests should not be collected in heparinized tubes, unless the specimens are used only for the PCV determination.

#### SPECIAL REPORT

*Laboratory Hematology*

**K<sub>2</sub>EDTA konsantrasyonu 1.5-2.2 mg/ml kan olarak önerilmiştir.**

## Recommendations of the International Council for Standardization in Haematology for Ethylenediaminetetraacetic Acid Anticoagulation of Blood for Blood Cell Counting and Sizing

INTERNATIONAL COUNCIL FOR STANDARDIZATION IN HAEMATOLOGY:  
EXPERT PANEL ON CYTOMETRY\*


Of the three ethylenediaminetetraacetic acid (EDTA) salts used for anticoagulation of blood specimens for hematologic testing, potassium salts are the most readily soluble. Tripotassium EDTA is dispensed as a liquid and thus causes a slight dilution of the specimen. This salt also has been shown to affect the red blood cell size more at increased concentrations and on storage than the dipotassium salt. Therefore, dipo-

tassium EDTA is recommended as the anticoagulant of choice in specimen collection for blood cell counting and sizing. The amount of dipotassium EDTA used is 1.5–2.2 mg (3.7–5.4  $\mu\text{mol}$ ) per milliliter of blood. (Key words: Anticoagulant; Blood cell count; EDTA) Am J Clin Pathol 1993;100:371–372.



# EDTA'ya Bağlı Psödotrombositopeni

- EDTA'nın, kalsiyum iyonlarını bağlarken trombosit membranında bulunan glikoprotein IIb-IIIa molekülüyle etkileşerek, glikoprotein IIb epitopunu açığa çıkardığı ve bu epitopa karşı otoantikora sahip kişilerde, trombositlerin kümelenmesine neden olduğu ileri sürülmektedir.
- Trombosit kümeleri büyüklüklerinden dolayı otomatik kan sayım cihazlarında trombosit olarak sayılamadıklarından, olduğundan daha düşük değerler raporlanmaktadır .



**Table 1** Major criteria for establishing a diagnosis of EDTA-dependent pseudothrombocytopenia.

- 
1. Platelet count typically  $<100 \times 10^9/L$
  2. Onset in only EDTA-anticoagulated sample kept at room temperature
  3. Time-dependent fall of the platelet count in the EDTA specimen
  4. Presence of platelet aggregates and clumps in EDTA-anticoagulated samples
  5. Lack of clinical signs or symptoms of platelet disorders
- 

**Table 2** Additives and other compounds used to prevent EDTA-dependent pseudothrombocytopenia.

- 
- Warming the sample at 37°C
  - Buffered sodium citrate
  - Lithium or calcium chloride heparin
  - Ammonium oxalate
  - $\beta$ -hydroxyethyltheophylline
  - Sodium fluoride
  - Trisodium citrate, pyridoxal 5'-phosphate and Tris (CPT)
  - Antiplatelet agents (e.g., acetylsalicylic acid, prostaglandin E1, apyrase, monoclonal antibodies)
  - Potassium azide
  - Kanamycin, amikacin and other aminoglycosides
- 

*Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med. 2012 Aug;50(8):1281-5. doi: 10.1515/cclm-2012-0081.*





Figure 2. WBC scattergram form on normal patient (left) and another one showing EDTA-induced PLT aggregates (right). PLT aggregates generate a rocket of particles of small and intermediate size (outing from the origin from the X-Y display), leading to inability to perform accurate identification of WBC (Bayer Advia 120). Ly, lymphocytes; LUC, large unstained cells; Mo, monocytes; PMN, polymorphonuclear neutrophils; Eo, eosinophils.

# Uygunsuz Hacim


- EDTA'lı tpn yetersiz doldurulması **Htc, MCV, MCHC, RDW** ve **RBC** etkilenecektir. **WBC ve RBC**'lerde morfolojik deęişiklikler olur.
- Fazla doldurulması ise tpn dzgn Őekilde karışmasını nler ve pıhtılaşmaya neden olur.
- CLSI/NCCLS tarafından test tplerinin nominal çekme hacminin **±% 10'una** kadar doldurulması nerilmektedir.



**Fig. 1** EDTA tubes from left to right: overfilled, correctly filled and underfilled.


# Tüplerin Karıştırılması

- Katkı maddesi içeren tüpler her numune alındıktan sonra yeterli karışımın sağlanması için (pıhtı, mikropıhtı ve fibrin filament oluşmasını önlemek için) özellikle üretici firmanın önerileri doğrultusunda nazikçe alt üst edilerek karıştırılmalıdır.
- Tüpler, numunelerde hemolize neden olacağından şiddetle çalkalanmamalıdır.



# Tüplerin Etiketlenmesi

- Hastanın kimlik doğrulaması ve kan alımı için uygunluğunun sorgulanmasından sonra tüpler etiketlenmelidir.
- **TBD. Venöz Kan Alma (Filebotomi) Kılavuzu,2015.**





# GP41-A6

## Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard—Sixth Edition

### 8.15 Step 15: Label Blood Collection Tubes and Record Time of Collection

The patient and the patient's blood specimen must be positively identified at the time of collection. Tubes must be positively identified after filling, not before, with a firmly attached label bearing at least the following:

- patient's first and last names;
- identification number;
- date;
- time (as required, eg, therapeutic drug monitoring); and
- identification of the person collecting the specimen.

The tube must be labeled with the above information before leaving the side of the patient. This may be accomplished by inscription or a computer-generated label or a bar-code label. There must be a mechanism to identify the person who drew the blood.<sup>14</sup> Where possible, compare the labeled tube to the patient's identification bracelet or have the patient verify that the information on the labeled tube is correct.

# Transport ve Depolama

**Table 3** Stability of haematology parameters in EDTA blood samples

Parameter	Storage at 4 °C	Effect of delayed processing
HGB	Stable up to 72 h	
RBC count	Stable up to 72 h	
MCV	Stable up to 6 – 12 h	Tends to increase
HCT	Stable up to 6 – 12 h	Tends to increase
PLT	Stable up to 24 h	
Reticulocytes (RET)	Stable up to 72 h	
WBC	Stable up to 72 h	

Table 2

Reccomendations for maximum allowable storage time (h) on EDTA anticoagulated blood

Test	Room temperature (18–22 °C)	Refrigerated (2–6 °C)
Blood smear	2–8 [2,14]	12–24 [5,12]
Complete blood count	6 [5,16]	24 [12]
Differential count	6 [5,16]	24 [12]
Reticulocytes	6 [15]	72 [15]

*Buttarelo M. Quality specification in haematology: the automated blood cell count. Clinica Chimica Acta 346 (2004) 45–54.*



# Pnömatik Sistem

## The pneumatic tube system does not affect complete blood count results; a validation study at a tertiary care hospital

A. Z. AL-RIYAMI\*, M. AL-KHABORI\*, R. M. AL-HADHRAMI†, I. S. AL-AZWANI†, H. M. DAVIS\*,  
K. S. AL-FARSI\*, S. S. ALKINDI\*, S. F. DAAR‡

\*Department of Hematology,  
Sultan Qaboos University  
Hospital, Muscat, Oman  
†College of Medicine and Health  
Sciences, Sultan Qaboos  
University, Muscat, Oman  
‡Department of Hematology,  
College of Medicine and Health  
Sciences, Sultan Qaboos  
University, Muscat, Oman

*Correspondence:*  
Arwa Z Al-Riyami,  
Department of Hematology,  
Sultan Qaboos University  
Hospital, PO Box 38, PC 123,  
Muscat, Oman.  
Tel.: (+968)24144370;  
Fax: (+968)24144887;  
E-mail: arwa@squ.edu.om

doi:10.1111/ijlh.12180

Received 29 July 2013; accepted  
for publication 18 November  
2013

### SUMMARY

**Introduction:** Effect of the pneumatic tube system (PTS) on sample quality is controversial. Herein we aim at evaluating the impact of sample transportation via the PTS on complete blood count (CBC) results.

**Methods:** Duplicate CBC samples from normal donors and anemic patients were sent in parallel to the laboratory for testing through the PTS and the courier (CO). We used scatter plots, Bland–Altman plots, correlation coefficient ( $r$ ), and coefficient of determination for the validation.

**Results:** A total of 115 samples (donors: 59, patients: 56) were tested. There was excellent correlation between both methods for red blood cell parameters ( $r$  range = 0.9213–0.9958) and platelet count. White blood cell (WBC) count and differential count showed similar results ( $r$  range = 0.8605–0.9821) for all, with exception of basophils which showed modest correlation ( $r = 0.4827$  for patients and 0.5758 for normal donors). Most of the differences in measurement of all CBC parameters were within the 95% confidence interval of the mean difference on Bland–Altman plots.

**Conclusion:** Modern PTS can be safely used for transporting CBC samples.



# The Effects of Sample Transport by Pneumatic Tube System on Routine Hematology and Coagulation Tests

TABLE 1: Summary of the differences in CBC between pneumatic tube samples and hand delivered samples.

S. no.	Paired samples	Mean difference	Standard deviation of mean difference	95% confidence interval of mean difference		P value
				Lower	Upper	
1	RBC P-RBC M ( $\times 10^{12}/l$ )	-.03	.21	-.08	.01	.11
2	HB P-HB M (g/dl)	-.01	.24	-.06	.05	.84
3	MCV P-MCV M (fl)	-.82	1.9	-1.28	-.37	.001
4	MCH P-MCH M (pg)	.03	.41	-.06	.12	.500
5	MCHCP-MCHC M (g/dl)	.36	.84	.17	.56	<0.001
6	RDW P-RDW M (%)	-.33	.67	-.49	-.18	<0.001
7	WBC P-WBC M ( $\times 10^9/l$ )	.04	1.2	-.24	.32	.759
8	NE P-NE M (%)	-.45	2.94	-1.13	.21	.182
9	LY P-LY M (%)	.20	3.30	-.55	.96	.590
10	MO P-MO M (%)	.30	1.37	-.01	.62	.057
11	EO P-EO M (%)	.28	3.46	-.50	1.08	.472
12	BA P-BA M (%)	.01	.33	-.06	.08	.754
13	PLT P-PLT M ( $\times 10^9/l$ )	.13	.26	.07	.19	<0.001
14	MPV P-MPV M (fl)	-.18	.64	-.32	-.03	.017

MCV  
MCHC  
RDW  
PLT

P: pneumatic tube samples; M: hand delivered samples; RBC: red blood cells count; HB: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; RDW: red cell distribution width; WBC: white blood cell count; NE: neutrophils; LY: lymphocytes; MO: monocytes; EO: eosinophils; BA: basophils; PLT: platelets; MPV: mean platelet volume

in PT and APTT samples compared to the hand delivered samples. **Conclusion.** Despite statistically significant changes in RBC parameters such as MCV, RDW, and MCHC and platelet count, these changes were clinically insignificant. Hence, blood samples for CBC and coagulation assay can safely be transported via our hospital's PTS. However, further studies on platelet count are warranted to ensure safe transport and accuracy of the results.

# Assessing Safety of Pneumatic Tube System (PTS) for Patients with Very Low Hematologic Parameters

Mustafa Koroglu  
 Mehmet Ali Erkurt  
 Irfan Kuku

1 Department of Hematology, Karabuk University, Faculty of Medicine, Karabuk, Turkey

2 Department of Hematology, Inonu University, Faculty of Medicine, Malatya, Turkey

3 Department of Biostatistics, Karabuk University, Faculty of Medicine, Karabuk,


Table 2. Descriptive statistics of blood analysis results for two types of transportation.

	Group 1		Group 2		P
WBC ( $\times 10^3/\mu\text{L}$ ) <sup>#</sup>	0.800	(0.100–7.800)	0.700	(0.100–7.700)	0.021
RBC ( $\times 10^3/\mu\text{L}$ ) <sup>*</sup>	3.012 $\pm$ 0.278		2.981 $\pm$ 0.282		0.000
HGB (g/dL) <sup>#</sup>	9.300	(7.200–10.900)	9.100	(7.000–10.300)	0.000
HCT (%) <sup>*</sup>	27.09 $\pm$ 2.28		26.56 $\pm$ 2.11		0.000
MCV (fL) <sup>#</sup>	89.00	(80.30–106.50)	88.80	(81.10–106.70)	0.29
MCH (pg) <sup>#</sup>	29.70	(26.80–33.70)	29.70	(27.00–32.60)	0.96
MCHC (g/dL) <sup>#</sup>	30.10	(26.80–33.70)	30.10	(27.00–33.70)	0.000
RDW <sup>#</sup>	15.0	(12.0–25.3)	15.0	(12.1–27.1)	0.94
PLT ( $\times 10^3/\mu\text{L}$ ) <sup>#</sup>	22.0	(2.0–64)	17.0	(9.0–63.0)	0.000
MPV (fL) <sup>#</sup>	7.85	(5.9–10.5)	7.8	(5.9–11.6)	0.81
LD (U/L) <sup>#</sup>	168.0	(56.0–815.0)	189.5	(60.0–847.0)	0.000
TB (mg/dL) <sup>#</sup>	0.97	(0.22–21.34)	0.97	(0.09–21.35)	0.70
CB (mg/dL) <sup>#</sup>	0.43	(0.13–16.5)	0.44	(0.14–16.48)	0.76
UB (mg/dL) <sup>#</sup>	0.52	(0.10–4.97)	0.49	(0.08–4.84)	0.000
AST (U/L) <sup>#</sup>	13.0	(4.0–82.0)	16.0	(4.0–82.0)	0.000
ALT (U/L) <sup>#</sup>	21.0	(3.0–158.0)	22.0	(6.0–159.0)	0.15
Potassium (K) (mmol/L) <sup>#</sup>	3.7	(2.3–6.8)	3.9	(2.5–6.9)	0.000

## Conclusions

In our study, we found that the PTS had a potential effect on routine hematological testing. Blood cell counts in patients with leukemia may be altered by the use of PTS transportation. Because each extra transfusion leads to an increase

# Hemoliz



- Hemoliz, eritrosit membranının bozulması ile Hb ve diğer intrasellüler maddelerin serum veya plazmaya geçmesidir.
- The Working Group on Laboratory Errors and Patient Safety (WG-LEPS) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 391 laboratuvarında yaptığı çalışmada

Hemolizli örneklerin %53 acil servisten,

%16 sı pediatri servisinden

% 7'sinin Yoğun Bakım Üniteleri

- *Giuseppe Lippi, Mario Plebani, Salvatore Di Somma & Gianfranco Cervellin (2011) Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories, Critical Reviews in Clinical Laboratory Sciences, 48:3, 143-153, DOI:10.3109/10408363.2011.600228*

# Hemoliz

- Hemolizin derecesine göre ve kullanılan ölçüm yöntemine göre değişmekle birlikte hemolizli örnekte;

- RBC
- Htc
- MCV
- MCHC
- RDW
- PLT



Most common situations causing hemolysis in EDTA specimens. <sup>10,11</sup>
When a tourniquet is too tight
Blood tube is vigorously mixed/shaken (mix gently 8-10 times)
Poor phlebotomy technique (probing for vein)
Specimen transportation conditions (time, temperature, etc.)
Vascular access devices
Specimen storage (should be 2-8oC for <24 hrs)
Over-clenching of fist
Needle size too small (use 23g or bigger)
Milking a finger-stick (newborns, geriatric, oncology patients)
Drawing specimen before alcohol dries (wait 30-60 seconds)
Over-centrifugation (time/speed)
Frozen EDTA tubes


# Lipemi

- Hematolojik testler de lipid ve şilomikronlardan etkilenir.
- Lipemik örneklerdeki bulanıklık spektrofotometrik ölçüm üzerinden interferansa bağlı olarak yanlış **yüksek Hb** ölçümüne neden olur. (MCHC>36 g/dl)
- **PLT, WBC ve Lenfositlerde** interferansa no.
- Lipitler yüksek hacimli damlacıklar oluşturduğunda, PLT sayımını engelleyebilirler.




# Hiperlökositoz

- $>100.000/\mu\text{l}$
- Hb
- RBC
- MCV
- PLT




# Soğuk Aglütininin

- Soğuk Aglütininin hastalığı karakteristik olarak eritrosit üzerindeki polisakkarit antijenlere yönelik oluşan genellikle IgM nadiren de IgA veya IgG tipindeki antikorların neden olduğu otoimmün bir hastalıktır .
- Soğuk aglütininin hastalığında soğukta aktifleşen antikorların eritrositlerin zarında dejenerasyon oluşturması ve eritrositlerin otoaglütinasyona uğraması sonucu hemoliz gerçekleşir.
- RBC ↓
- Htc ↓
- MCV ↑
- MCH ↑
- MCHC ↑








**FIGURE 2.** A proposed laboratory procedure for whole blood samples with suspected cold agglutinins. CBC - complete blood count. Hct - haematocrit. MCV - mean corpuscular volume. MCH - mean corpuscular haemoglobin. MCHC - mean corpuscular haemoglobin concentration. RDW - red cell distribution width. Plt - platelet. MPV - mean platelet volume. WBC - white blood cells. CAs - cold agglutinins.

**Topic A. et al. Effect of cold agglutinins on red blood cell parameters in a trauma patient: a case report. *Biochem Med (Zagreb)* 2018;28():031001**

# Kriyoglobulinler

- Genellikle 37°C den düşük sıcaklıkta presipite olarak, yüksek moleküler ağırlıklı agregatlar meydana getiren immunglobulinlerdir.
- Kriyoglobulinler de otomatik kan sayımı sonuçlarını etkileyerek **lökosit ve trombosit sayılarının yüksek çıkmasına** neden olurlar.



**Table 3. Laboratory mistakes in stat testing.**

Defects detection steps	Defects found	
	No.	Frequency, %
<i>Preanalytical</i>		
Wrong name of patient given	5	2.6
Erroneous specification of hospital unit	36	19.0
Physician's order missed	34	18.1
Order misinterpreted	6	3.2
Inappropriate container used	5	2.6
Specimen collection incorrect	4	2.1
<u>Specimen collected from infusion route</u>	39	<u>20.6</u>
Subtotal	129	68.2
<i>Analytical</i>		
Isolated malfunctioning of instrument	5	2.6
Lack of specificity of the method	4	2.1
Unacceptable performance	16	8.5
Subtotal	25	13.3
<i>Postanalytical</i>		
Correction of erroneous finding overlooked	9	4.8
Keyboard entry error	5	2.6
Turnaround time exceeded	6	3.2
Physician not notified of problem	15	7.9
Subtotal	35	18.5

*Plebani M, Carraro P. Mistakes in a STAT laboratory: types and frequency. Clin Chem 1997;43:1348–51*

**Table 1. Laboratory errors in stat testing.**

Defects: detection steps	Defects found	
	No.	Frequency, %
<i>Preanalytical</i>		
Specimen collected from infusion route	3	1.9
Sample contaminated	1	0.6
<u>Tube filling error</u>	21	<u>13.1</u>
Empty tube	11	6.9
Inappropriate container	13	8.1
Nonrefrigerated sample	3	1.9
Missing tube	5	3.1
Digoxin test timing error	1	0.6
Patient identification error	14	8.8
Request procedure error	12	7.5
Data communication conflict	6	3.8
Physician's request order missed	3	1.9
Order misinterpreted	2	1.3
Check-in not performed (in the Laboratory Information Systems)	4	2.5
Subtotal	99	61.9
<i>Analytical</i>		
Instrument-caused random error	3	1.9
Analytical inaccuracy not recognized	21	13.1
Subtotal	24	15
<i>Postanalytical</i>		
Results communication breakdown	32	20
Lack of communication within laboratory	3	1.9
TAT excessive	2	1.3
Subtotal	37	23.1

*Plebani M, Carraro P. Errors in a Stat Laboratory: Types and Frequencies 10 Years Later. Clin Chem 2007;53:1388–42*

**Table 1** Distribution of rejected blood samples and type of preanalytical error detected according to the analytical test requested and the requesting department.

	Rejected samples, n (%)					
	HS	MS	IVS	CS	WS	Total
<b>Requested tests</b>						
Clinical chemistry (n=9106)	242 (39.5)	16 (2.6)	–	–	50 (8.2)	308 (50.2)
Blood gases (n=2537)	–	29 (4.7)	–	37 (6.0)	–	66 (10.8)
<u>Blood counts (n=9052)</u>	–	9 (1.5)	–	25 (4.1)	–	34 (5.5)
Coagulation (n=5715)	67 (10.9)	28 (4.6)	64 (10.4)	28 (4.6)	18 (2.9)	205 (33.4)
<b>Requesting departments</b>						
<u>Emergency (n=14,525)</u>	229 (37.3)	42 (6.8)	35 (5.7)	47 (7.7)	35 (5.7)	388 (63.3)
ICU (n=5471)	12 (1.95)	14 (2.3)	14 (2.3)	10 (1.6)	19 (3.1)	69 (11.3)
Walk-in clinic (n=1285)	19 (3.1)	3 (0.49)	–	2 (0.32)	–	24 (3.9)
Hospitalisation ward (n=5129)	49 (8.0)	23 (3.7)	15 (2.4)	31 (5.1)	14 (2.3)	132 (21.5)
Overall mistakes, n (%)	309 (50.4)	82 (13.4)	64 (10.4)	90 (14.7)	68 (11.1)	613 (100)

ICU, intensive care unit; HS, haemolysed sample; MS, missed sample; IVS, inappropriate volume sample; CS, coagulated sample; WS, wrong sample.

*Romero A. et al. Identification of preanalytical mistakes in the stat section of the clinical laboratory. Clin Chem Lab Med 2005;43(9):974–975*

**TABLE 1.** Specimen rejection rates according to the error reasons.

Laboratory test groups	Improperly labelled samples (%)	Hemolysis (%)	Clotted specimen (%)	Insufficient volume (%)
Clinical chemistry inpatient	0.03*	0.06	0	0.01
Clinical chemistry outpatient	0	0	-	0
Immunoassay	0	0	-	0.10
Coagulation	0.02	0.48	0.26	1.38**
HbA1c	0.01	-	0.01	0.01
<u>Hematology</u>	0.01	-	0.16*	0.02
ESR	0.01	-	0.64*	0.25

Percentages were calculated by 'number of rejected samples' / total number of samples' of each laboratory test unit for a 1 year period. \*P=0.027 among other test groups, \*\*P < 0.001 among other error reasons.

ESR - erythrocyte sedimentation rate.

*Atay A. Et al. Clinical biochemistry laboratory rejection rates due to various types of preanalytical errors. Biochem Med (Zagreb). 2014 Oct 15;24(3):376-82.*

- **Pıhtılı örnek; Toplam reddedilen örneklerde %14**  
**Reddedilen hematoloji örneklerinde ise % 65**

*Alsina, et al. Preanalytical quality control program – an overview of results (2001–2005 summary) Clin Chem Lab Med 2008;46(6):849–854*

*Jones, et al. Complete blood count specimen acceptability. A CAP Q-Probes study of 703 laboratories. Arch Pathol Lab Med V119, March 1995*

**Table 3. The error frequencies rate of laboratory QIs according to laboratories**

	Total rejected samples	Biochemistry, %	Immunoassays, %	HbA1C, %	Hematology, %	Urinalysis, %	Blood gases, %	Coagulation, %	ESR, %	Total, %
Total samples	169717	110856	27073	205068	54412	10009	41134	30732	649001	
<b>Pre-analytical phase</b>										
Inappropriate test request	16	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Misidentification error	59	0.00	0.01	0.00	0.01	0.00	0.01	0.02	0.07	0.01
Incorrect container	446	0.05	0.06	0.08	0.04	0.03	0.19	0.14	0.32	0.07
Incorrect sample type	148	0.02	0.02	0.00	0.01	0.01	0.14	0.09	0.08	0.02
Insufficient sample volume	756	0.04	0.04	0.04	0.08	0.10	0.17	0.83	0.14	0.12
Sample hemolyzed	501	0.22	0.01	0.00	0.01	0.00	0.00	0.23	0.00	0.08
<u>Sample clotted</u>	1842	0.00	0.00	0.53	0.58	0.00	2.18	0.44	0.33	0.28
Samples not delivered	42	0,01	0.01	0.00	0.00	0.00	0.03	0.00	0.00	0.01
Unsuitable transportation	35	0.02	0.00	0.00	0.00	0.00	0.01	0.00	0,00	0.01
Excessive transportation time	6	0,002	0.00	0.00	0.001	0,00	0.00	0.00	0.00	0,00
Other	35	0.01	0.01	0.00	0,00	0,01	0,02	0,01	0,00	0,01
<b>Analytical phase</b>										
Analyzer fault	13	0.004	0.00	0.00	0.00	0.00	0.002	0,005	0,00	0.002
Device pipetting error	4	0,002	0.000	0.00	0.00	0.00	0.00	0.002	0.00	0.001
Unacceptable performance in EQA	62	0.03	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.01
<b>Post-analytical phase</b>										
Inappropriate turnaround time	792	0.05	0.22	0.17	0.04	0.17	0.47	0.35	0.19	0.12
Total error rate	4757	0.48	0.38	0.83	0.78	0.31	3.24	2.13	1.15	0.73

This table describes the error percentage for all samples (total number of samples: 649,001). The formula of the error frequency rate: % rejected samples/total number of samples.

ESR: Erythrocyte sedimentation rate; EQA: External quality assurance; HbA1c: Glycated hemoglobin.

**Alpdemir M.et al. Evaluation of biochemistry laboratory quality indicators according to the national Laboratory Error Classification System. Int J Med Biochem 2018;1(2):65-71**

**Table 4. Error percentage by phase according to location of the error**

	<b>Pre-analytical phase, % (n=3886)</b>	<b>Analytical phase, % (n=79)</b>	<b>Post-analytical phase, % (n=792)</b>	<b>Total, % (n=4757)</b>
Clinic	19.6	-	-	16.0
Intensive care unit	19.6	-	-	16.0
<u>Emergency department</u>	<u>25.6</u>	-	-	20.9
Outpatient clinic	12.7	-	-	10.4
Sample receiving unit	22.1	-	-	18.1
Sample acceptance unit	-	-	-	-
Laboratory	0.4	100.0	100.0	18.6
Other	-	-	-	-

*Alpdemir M.et al. Evaluation of biochemistry laboratory quality indicators according to the national Laboratory Error Classification System. Int J Med Biochem 2018;1(2):65-71*

**TABLE 2.** Quality indicators of the preanalytical phase proposed by the IFCC Working Group - Laboratory Errors and Patient Safety (IFCC WG-LEPS) and sample rejection ratios (SRRs) in the emergency laboratory of Hacettepe University.

Quality Indicators of the pre-analytical phase proposed by the IFCC WG-LEPS	SRRs in the emergency laboratory of Hacettepe University (%)
<b>Patient identification</b>	
Number of requests with errors concerning patient identification/Total number of requests	0.1
<b>Data entry of the request</b>	
Number of requests with errors concerning test input (missing or added or misinterpreted) / Total number of requests	1.4
<b>Sample identification</b>	
Number of improperly labeled samples / Total number of samples	0.2
<b>Sample collection</b>	
Number of samples collected in inappropriate container / Total number of samples	3.6
Number of samples with insufficient sample volume / Total number of samples	22
<b>Transport of sample</b>	
Number of damaged samples / Total number of samples	0.2
Number of samples transported at inappropriate time / Total number of samples	3.4
Number of samples transported under inappropriate temperature / Total number of sample	1.2
Number of improperly stored samples / Total number of samples	0.4
Number of samples lost-not received / Total number of samples	0.2
<b>Suitability of sample</b>	
Number of samples with inadequate sample-anticoagulant ratio / Total number of samples	34.9
Number of fibrin clotted samples / Total number of samples	27.9
Number of hemolyzed samples / Total number of samples	2.2
Number of lipemic samples / Total number of samples	0.1
Number of samples contaminated by intravenous infusion / Total number of samples	2.2

SRR - sample rejection ratio



- Türk Biyokimya Derneđi  
Preanalitik Evre alıřma  
Grubu -2014
- Venöz Kan Alma Kılavuzu-  
2015
- Tıbbı Laboratuvarlarda  
Santrifüj Kullanım  
Kılavuzu,2017



TÜRK BİYOKİMYA DERNEĐİ

TIBBİ LABORATUVARLARDA  
SANTRİFÜJ KULLANIM  
KILAVUZU

ISBN: 978-605-87229-4-1



VENÖZ KAN ALMA  
(FİLEBOTOMİ)  
KILAVUZU


Türk Biyokimya Derneđi Preanalitik Evre alıřma Grubu tarafından hazırlanmıřtır.

2015-ANKARA

ISBN 978-605-87229-3-4

EFLM - European Federation of Clinical Chemistry and Laboratory Medicine

https://www.eflm.eu/site/page/a/1194




EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Keep updated with EFLM activities! Join the EFLM circulation list here.

WHO WE ARE | CONGRESS CALENDAR | EFLM PUBLICATIONS | EFLM MEMBERS | EXECUTIVE BOARD | GENERAL PUBLIC | CONTACT US

Click on the flag to reach the website of EFLM National Societies



Working Group: Preanalytical Phase

Back Home

Forthcoming EFLM events

- 5th EFLM Preanalytical Conference
- XXIII EuroMedLab Barcelona 2019
- Symposium CELME 2019

Partners

Resources / Educational Material

Articles

**Preanalytical challenges – time for solutions**  
 Lippi G, Betsou F, Cadamuro J, Comes M, Fleischhacker M, Fruekilde P, Neumaier M, Nybo M, Padoan A, Plebani M, Soicovelli L, Vermeersch P, von Meyer A, Simunic AM, on behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)  
 Clin Chem Lab Med 2019 doi:10.1515/oclm-2018-1334  
 Click here to download the paper

**Joint EFLM-COLABIOLCI Recommendation for venous blood sampling v 1.1, June 2018**  
 Simundic AM, Bolenius K, Cadamuro J, Church S, Comes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GBB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P, on behalf of the Working Group for Preanalytical Phase (WG-PRE), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOLCI)  
 Clin Chem Lab Med 2018 doi:10.1515/oclm-2018-0602

This website uses cookies to ensure you get the best experience on our website. FIND MORE | ACCEPT

**Table 1: Activities of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).**

**Finalized projects**

- Harmonization of fasting status
- Harmonization of patient and blood tubes identification
- Harmonization of color-coding of blood collection tubes
- Harmonization of the sequence of blood tubes to be followed during blood drawing
- Harmonization of preanalytical quality indicators
- Guidance on local validation of blood collection tubes
- Performance and publication of two European surveys on blood sampling procedures
- Organization of four international meetings
- Walter Guder Preanalytical Award

**Ongoing projects**

- Development and validation of an external quality assessment (EQA) scheme on preanalytical variables
- Development and dissemination of a survey about local management of unsuitable samples
- Release of EFLM phlebotomy guidelines
- Organization of webinars for harmonizing preanalytical activities

# Sonuç ve Öneriler

- Multidisipliner yaklaşım
- Harmonizasyon, standardizasyon
- Kalite indikatörleri
- Sürekli eğitim ve takip
- Preanalitik ve postanalitik faz-Eksternal Kalite Kontrol
- **Medical laboratories - Particular requirements for quality and competence (ISO 15189:2012)**

“5.6.4. External quality assessment programmes should, as far as possible, provide clinically relevant challenges that mimic patient samples and have the effect of checking the entire examination process, including pre-and post-examination procedures.”



# Teşekkürler...

